...
首页> 外文期刊>Journal of Endocrinological Investigation: Official Journal of the Italian Society of Endocrinology >Hypothalamus-pituitary-adrenal axis in central diabetes insipidus: ACTH and cortisol responsiveness to CRH administration.
【24h】

Hypothalamus-pituitary-adrenal axis in central diabetes insipidus: ACTH and cortisol responsiveness to CRH administration.

机译:中枢尿崩症的下丘脑-垂体-肾上腺轴:ACTH和皮质醇对CRH的反应。

获取原文
获取原文并翻译 | 示例
           

摘要

A strong relationship has been found between arginine-vasopressin (AVP) and hypothalamus-pituitary-adrenal axis in humans. The aim of the current study was to evaluate baseline and CRH-stimulated ACTH and F levels in patients with central diabetes insipidus (CDI), before and after replacement therapy with desamino-D-AVP (DDAVP). Twenty-five patients with CDI, and 25 sex- and age- and BMI-matched healthy subjects entered the study. A standard CRH test (measurement of plasma ACTH and serum F before and every 15 min for 2 h after the administration of 100 microg of human CRH) was performed in all subjects. In patients with CDI, CRH test were repeated after 1 week of DDAVP at standard doses. At study entry, ACTH and F levels were significantly higher in patients with CDI than in controls either at baseline (ACTH: 45.5+/-4.8 vs 18.5+/-3.3 ng/l, p<0.05; F: 375.1+/-55.7 vs 146.6+/-19.4 microg/l, p<0.05) or after CRH test considered as a peak (ACTH: 90.8+/-14.4 vs 42.5+/-7.4 ng/l, p<0.05; F: 501.6+/-65.7 vs 226.3+/- 25.6 microg/l, p<0.05) and AUC (ACTH: 3997.0+/-571.7 vs 2136.0+/-365.8 ng/l/120 min, p<0.05; F: 31,489.0+/-4299.4 vs 14,854.5+/-1541.5 microg/l/120 min, p<0.05). In patients with CDI, 1 week of replacement with DDAVP brought down ACTH (peak: 56.9+/-9.3 ng/l; AUC: 2390.7+/-480.7 ng/l/120 min) and F (peak: 310.3+/-39.5 microg/l; AUC: 17,555.5+/-2008.7 microg/l/120 min) responses to CRH to normal but did not significantly modify baseline hormone levels (ACTH: 29.6+/-3.6 ng/l; F: 239.0+/-32.3 microg/l). In conclusion, CDI is associated to increased baseline ACTH and F levels and increased responsiveness of ACTH and F to CRH administration. In addition, replacement treatment with DDAVP normalized CRH-induced but not baseline ACTH and F secretion.
机译:已发现人类的精氨酸-加压素(AVP)与下丘脑-垂体-肾上腺轴之间存在很强的关系。本研究的目的是评估在用去氨基-D-AVP(DDAVP)替代治疗前后中枢性尿崩症(CDI)患者的基线水平和CRH刺激的ACTH和F水平。 25名CDI患者以及25名性别,年龄和BMI匹配的健康受试者进入了研究。在所有受试者中进行标准CRH测试(在施用100微克人CRH之前和之后每15分钟测量血浆ACTH和血清F,持续2小时)。对于CDI患者,标准剂量的DDAVP 1周后重复进行CRH测试。在研究开始时,在基线时,CDI患者的ACTH和F水平显着高于对照组(ACTH:45.5 +/- 4.8与18.5 +/- 3.3 ng / l,p <0.05; F:375.1 +/- 55.7 vs 146.6 +/- 19.4 microg / l,p <0.05)或CRH测试后视为峰值(ACTH:90.8 +/- 14.4 vs 42.5 +/- 7.4 ng / l,p <0.05; F:501.6 +/- 65.7 vs 226.3 +/- 25.6 microg / l,p <0.05)和AUC(ACTH:3997.0 +/- 571.7 vs 2136.0 +/- 365.8 ng / l / 120 min,p <0.05; F:31,489.0 +/- 4299.4 vs 14,854.5 +/- 1541.5 microg / l / 120分钟,p <0.05)。在CDI患者中,DDAVP替代治疗1周降低了ACTH(峰值:56.9 +/- 9.3 ng / l; AUC:2390.7 +/- 480.7 ng / l / 120分钟)和F(峰值:310.3 +/- 39.5 microg / l; AUC:17,555.5 +/- 2008.7 microg / l / 120分钟)对正常的CRH反应,但并未显着改变基线激素水平(ACTH:29.6 +/- 3.6 ng / l; F:239.0 +/- 32.3微克/升)。总之,CDI与基线ACTH和F水平升高以及ACTH和F对CRH给药的反应性增加相关。另外,用DDAVP替代治疗可使CRH诱导的正常化,但不能使基线ACTH和F分泌正常化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号